188 related articles for article (PubMed ID: 28689816)
1. A novel role for dopamine signaling in the pathogenesis of bone loss from the atypical antipsychotic drug risperidone in female mice.
Motyl KJ; Beauchemin M; Barlow D; Le PT; Nagano K; Treyball A; Contractor A; Baron R; Rosen CJ; Houseknecht KL
Bone; 2017 Oct; 103():168-176. PubMed ID: 28689816
[TBL] [Abstract][Full Text] [Related]
2. Propranolol Attenuates Risperidone-Induced Trabecular Bone Loss in Female Mice.
Motyl KJ; DeMambro VE; Barlow D; Olshan D; Nagano K; Baron R; Rosen CJ; Houseknecht KL
Endocrinology; 2015 Jul; 156(7):2374-83. PubMed ID: 25853667
[TBL] [Abstract][Full Text] [Related]
3. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of low-dose risedronate against osteocyte apoptosis and bone loss in ovariectomized rats.
Ye T; Cao P; Qi J; Zhou Q; Rao DS; Qiu S
PLoS One; 2017; 12(10):e0186012. PubMed ID: 29045447
[TBL] [Abstract][Full Text] [Related]
5. Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain.
Motyl KJ; Dick-de-Paula I; Maloney AE; Lotinun S; Bornstein S; de Paula FJ; Baron R; Houseknecht KL; Rosen CJ
Bone; 2012 Feb; 50(2):490-8. PubMed ID: 21854880
[TBL] [Abstract][Full Text] [Related]
6. Bone loss associated with hyperprolactinemia in patients with schizophrenia.
Kinon BJ; Liu-Seifert H; Stauffer VL; Jacob J
Clin Schizophr Relat Psychoses; 2013 Oct; 7(3):115-23. PubMed ID: 23395836
[TBL] [Abstract][Full Text] [Related]
7. Topically administered Risedronate shows powerful anti-osteoporosis effect in ovariectomized mouse model.
Nam SH; Jeong JH; Che X; Lim KE; Nam H; Park JS; Choi JY
Bone; 2012 Jan; 50(1):149-55. PubMed ID: 22036912
[TBL] [Abstract][Full Text] [Related]
8. Understanding Mechanisms Underlying Non-Alcoholic Fatty Liver Disease (NAFLD) in Mental Illness: Risperidone and Olanzapine Alter the Hepatic Proteomic Signature in Mice.
Rostama B; Beauchemin M; Bouchard C; Bernier E; Vary CPH; May M; Houseknecht KL
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33302598
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of substance P signaling aggravates the bone loss in ovariectomy-induced osteoporosis.
Zheng XF; Zhao ED; He JY; Zhang YH; Jiang SD; Jiang LS
Prog Biophys Mol Biol; 2016 Nov; 122(2):112-121. PubMed ID: 27237582
[TBL] [Abstract][Full Text] [Related]
10. Risperidone accelerates bone loss in rats with autistic-like deficits induced by maternal lipopolysaccharides exposure.
Amini A; Namvarpour Z; Namvarpour M; Raoofi A
Life Sci; 2020 Oct; 258():118197. PubMed ID: 32781059
[TBL] [Abstract][Full Text] [Related]
11. Thermoneutral housing does not rescue olanzapine-induced trabecular bone loss in C57BL/6J female mice.
Langlais AL; Mountain RV; Kunst RF; Barlow D; Houseknecht KL; Motyl KJ
Biochimie; 2023 Jul; 210():50-60. PubMed ID: 37236340
[TBL] [Abstract][Full Text] [Related]
12. In utero exposure to atypical antipsychotic drug, risperidone: Effects on fetal neurotoxicity in hippocampal region and cognitive impairment in rat offspring.
Singh KP; Singh MK
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Apr; 75():35-44. PubMed ID: 28062214
[TBL] [Abstract][Full Text] [Related]
13. Intermittent on/off prostaglandin E2 and risedronate are equally anabolic as daily PGE2 alone treatment in cortical bone of ovariectomized rats.
Ma YF; Pan Z; Jee WS; Lin CH; Liang HH; Chen H; Pun S; Li XJ
J Bone Miner Res; 1997 Dec; 12(12):2108-12. PubMed ID: 9421244
[TBL] [Abstract][Full Text] [Related]
14. Clozapine affects the pharmacokinetics of risperidone and inhibits its metabolism and P-glycoprotein-mediated transport in vivo and in vitro: A safety attention to antipsychotic polypharmacy with clozapine and risperidone.
Liu X; Sun H; Zhang Y; Sun Y; Wang W; Xu L; Liu W
Toxicol Appl Pharmacol; 2021 Jul; 422():115560. PubMed ID: 33957192
[TBL] [Abstract][Full Text] [Related]
15. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
[TBL] [Abstract][Full Text] [Related]
16. Strain-dependent variations in the response of cancellous bone to ovariectomy in mice.
Iwaniec UT; Yuan D; Power RA; Wronski TJ
J Bone Miner Res; 2006 Jul; 21(7):1068-74. PubMed ID: 16813527
[TBL] [Abstract][Full Text] [Related]
17. Effects of prenatal exposure to antipsychotic risperidone on developmental neurotoxicity, apoptotic neurodegeneration and neurobehavioral sequelae in rat offspring.
Singh KP; Singh MK; Singh M
Int J Dev Neurosci; 2016 Aug; 52():13-23. PubMed ID: 27184437
[TBL] [Abstract][Full Text] [Related]
18. Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.
Carvalho RC; Fukushiro DF; Helfer DC; Callegaro-Filho D; Trombin TF; Zanlorenci LH; Sanday L; Silva RH; Frussa-Filho R
Addict Biol; 2009 Jul; 14(3):283-93. PubMed ID: 19298320
[TBL] [Abstract][Full Text] [Related]
19. [Neuroleptic malignant syndrome and atypical antipsychotics: a brief review].
Khaldi S; Kornreich C; Choubani Z; Gourevitch R
Encephale; 2008 Dec; 34(6):618-24. PubMed ID: 19081460
[TBL] [Abstract][Full Text] [Related]
20. Exploring mechanisms of increased cardiovascular disease risk with antipsychotic medications: Risperidone alters the cardiac proteomic signature in mice.
Beauchemin M; Geguchadze R; Guntur AR; Nevola K; Le PT; Barlow D; Rue M; Vary CPH; Lary CW; Motyl KJ; Houseknecht KL
Pharmacol Res; 2020 Feb; 152():104589. PubMed ID: 31874253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
